The mission of Altasciences is to deliver solutions that eliminate the need for several service providers and limits the number of deliveries during the early phases of drug development. Altasciences is an early-stage contract research organization with a distinctive company committed to supporting drug development from the selection of lead candidates to proof of concept. The company offers pre-clinical and clinical solutions to an international client base of biopharmaceutical companies with fewer bottlenecks, faster progression, and lower costs. The company continually seeks ways of improving relationships and the range of abilities in order to establish an environment that gives value to its customers, respect for its participants, research animals, and overall growth for its employees. Altasciences provides a flexible and personal approach, working as an extension of customers to meet even more complex needs and build strong partnerships along the way.
The company’s solution offering encompasses IND/NDA toxicology, safety pharmacology, and laboratory services for all small and large molecules, which meet global regulatory requirements. Altasciences continues to focus on animal welfare and enrichment and knows the importance of compassion, sensitivity, and compliance with regulatory guidelines. Medical experts from Altasciences use preclinical data and in-depth discussions to design, perform, and report clinical studies in a wide area of therapeutic areas. Altasciences has successfully completed hundreds of clinical pharmacology studies, with more than 600 beds and a combined database of more than 225,000 participants every year. In addition, the network of specialized clinicians and local hospital relationships provide access to a variety of patient populations. All studies are carried out with the highest standards of safety and conformity. In addition to sponsor audits, successful regulatory inspections are regularly conducted by agencies such as with the FDA, Health Canada, ANVISA, MHRA, and SCC.
Altasciences has successfully completed a major first-in-human (FIH), Phase-I, an integrated adaptive clinical trial like single and multiple ascending doses (SAD and MAD), project management, bioanalysis, and medical writing for Bellus Health sponsor. From the recruitment of 90 subjects to the management of all aspects of this extremely important FIH test, Altasciences had to use a flexible and adaptive strategy to fully satisfy customer needs. The contributions of Altasciences have enabled Bellus Health to make a well-informed decision to move ahead with its lucrative chronic cough drug candidate. The large participant databases of the company allow rapid recruitment and constantly optimize its procedures and offerings to better satisfy the needs of sponsors.